Hydrochloric Acid

Hydrochloric Acid

SCHEMBL120260

CCCCCCCCCCCCCCCCCC(C=O)(C=O)NCc1ccccc1.Cl

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 known ✓ Q99720 1/20 0.41
MAOA known ✓ P21397 1/20 0.39
S1PR2 known ✓ O95136 1/20 0.39
S1PR4 known ✓ O95977 1/20 0.39
S1PR1 known ✓ P21453 1/20 0.39
S1PR3 known ✓ Q99500 1/20 0.39
EPHX2 P34913 5/20 0.46
FAAH O00519 2/20 0.43
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PKM P14618 1/20 0.39
ADH1B P00325 1/20 0.39
ADH1C P00326 1/20 0.39
ADH1A P07327 1/20 0.39
ADH7 P40394 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
NAAA Q02083 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19411953 0.98 EPHX2 (0.47) EPHX2FAAHCNR1CNR2L3MBTL1
Hydrochloric Acid SCHEMBL8900595 0.80 EPHX2 (0.47) EPHX2FAAHCNR1CNR2L3MBTL1
Hydrochloric Acid SCHEMBL9725437 0.78 EPHX2 (0.46) EPHX2FAAHCNR1CNR2L3MBTL1
Hydrochloric Acid SCHEMBL11150761 0.78 EPHX2 (0.46) EPHX2FAAHCNR1CNR2L3MBTL1
Hydrochloric Acid SCHEMBL8417309 0.78 EPHX2 (0.46) EPHX2FAAHCNR1CNR2L3MBTL1
Hydrochloric Acid SCHEMBL2232233 0.78 EPHX2 (0.46) EPHX2FAAHCNR1CNR2L3MBTL1
Hydrochloric Acid SCHEMBL28716627 0.78 EPHX2 (0.46) EPHX2FAAHCNR1CNR2L3MBTL1
Hydrochloric Acid SCHEMBL356747 0.78 EPHX2 (0.46) EPHX2FAAHCNR1CNR2L3MBTL1
Hydrochloric Acid SCHEMBL3299241 0.78 EPHX2 (0.46) EPHX2FAAHCNR1CNR2L3MBTL1
Hydrochloric Acid SCHEMBL8988138 0.77 EPHX2 (0.45) EPHX2FAAHCNR1CNR2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109983172-A Antibacterial regenerated celulose fibre and preparation method thereof 格拉姆工业有限公司 2019-07-05 CN claimed
CN-109152725-A For handling the composition of keratin fiber 莱雅公司 2019-01-04 CN claimed
CN-108024920-A Include the liquid cosmetic composition and lip processing method of high non-volatile oil content 莱雅公司 2018-05-11 CN claimed
CN-107427425-A For adjusting the composition of hair 莱雅公司 2017-12-01 CN claimed
CN-105492079-A Composition comprising an aminosilicone, a cationic surfactant, an associative polymer and a thickener OREAL 2016-04-13 CN claimed
US-12233139-B2 Oral care compositions containing a gel network phase THE PROCTER & GAMBLE COMPANY (US) 2025-02-25 US disclosed
EP-2533719-B1 METHOD OF PRODUCING A COATED DENTAL FLOSS, AND DENTAL FLOSS PROCTER & GAMBLE (US) 2024-05-08 EP disclosed
US-20230104890-A1 Oral Care Compositions Containing A Gel Network Phase PROCTER & GAMBLE (US) 2023-04-06 US disclosed
US-11517509-B2 Oral care compositions containing a gel network phase THE PROCTER & GAMBLE COMPANY (US) 2022-12-06 US disclosed
US-11484487-B1 Gingivitis gum serum ROBELL RESEARCH, INC. (US) 2022-11-01 US disclosed
US-20220257484-A1 WHOLE MOUTH MALADOR CONTROL BY A COMBINATION OF ANTIBACTERIAL AND DEODORIZING AGENTS PROCTER & GAMBLE (US) 2022-08-18 US disclosed
EP-2424621-B1 METHODS FOR IMPROVING TASTE AND ORAL CARE COMPOSITIONS WITH IMPROVED TASTE PROCTER & GAMBLE (US) 2021-11-03 EP disclosed
WO-2010019730-A1 SYNTHESIS OF CYCLOHEXANE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS THE PROCTER & GAMBLE COMPANY (US) 2010-02-18 WO disclosed
WO-2010004361-A2 COMPOSITIONS AND METHODS FOR IMPROVING OVERALL TOOTH HEALTH AND APPEARANCE THE PROCTER & GAMBLE COMPANY (US) 2010-01-14 WO disclosed
US-20080247973-A1 Compositions and Methods for Improving Overall Tooth Health and Appearance THE PROCTER & GAMBLE COMPANY 2008-10-09 US disclosed
CN-1917848-A Sun-block cosmetic SHISEIDO CO LTD (JP) 2007-02-21 CN disclosed
EP-1708791-A1 ORAL CARE COMPOSITIONS COMPRISING INCREASED BIOAVAILABLE LEVELS OF QUATERNARY AMMONIUM ANTIMICROBIALS The Procter and Gamble Company (US) 2006-10-11 EP disclosed
WO-2005072693-A1 ORAL CARE COMPOSITIONS COMPRISING INCREASED BIOAVAILABLE LEVELS OF QUATERNARY AMMONIUM ANTIMICROBIALS THE PROCTER & GAMBLE COMPANY (US) 2005-08-11 WO disclosed
US-20050169852-A1 Oral care compositions comprising increased bioavailable levels of quaternary ammonium antimicrobials THE PROCTER & GAMBLE COMPANY (US) 2005-08-04 US disclosed
US-5405604-A Oil in water emulsion containing microbiocidal quaternary ammonium compound, solvent/carrier, flavoring oil and water, for aqueous mouthwash concentrate to be diluted with water which breaks emulsion and turns mixture cloudy THE PROCTER & GAMBLE COMPANY (US) 1995-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12233139-B2 Oral care compositions containing a gel network phase FLNA, FLNB, FRG1 SIGMAR1 1719/4885MAOA 4653/4885S1PR2 317/4885
US-20230104890-A1 Oral Care Compositions Containing A Gel Network Phase FLNA, FLNB, FRG1 SIGMAR1 1719/4885MAOA 4653/4885S1PR2 317/4885
US-11517509-B2 Oral care compositions containing a gel network phase FLNA, FLNB, AP1G1 SIGMAR1 1551/4885MAOA 4501/4885S1PR2 625/4885
US-20220257484-A1 WHOLE MOUTH MALADOR CONTROL BY A COMBINATION OF ANTIBACTERIAL AND DEODORIZING AGENTS OR10J3, HDAC10, RPP30 SIGMAR1 81/4885MAOA 2363/4885S1PR2 2090/4885
US-20080247973-A1 Compositions and Methods for Improving Overall Tooth Health and Appearance ALPP, CHERP, CA3 SIGMAR1 2178/4885MAOA 4310/4885S1PR2 2904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.